Navigation Links
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
Date:6/30/2008

involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk that ELADUR may not be the first bupivacaine product approved for PHN, DURECT's ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of ELADUR, obtain product and manufacturing approvals from regulatory agencies and manufacture and commercialize ELADUR, as well as marketplace acceptance of the product candidate. Further information regarding these and other risks is included in DURECT's Form 10-Q dated May 8, 2008 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
5. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
9. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
(Date:9/30/2014)... , Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... specializes in the research, development and commercialization of prescription ... $25 million advance from Hercules Technology Growth Capital, Inc. ... the second and final advance under the Loan and ... United Kingdom , Alimera Sciences Limited, entered into ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
Breaking Medicine Technology:Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Feb. 16, 2011 U.S. Marshals, at the ... yesterday seized all lots of Auralgan Otic Solution, ... inflammation associated with ear infections, from Integrated Commercialization ... manufactured for Deston Therapeutics, located in Chapel Hill, ...
... 16, 2011 Spending on specialty medications is growing ... medications can help slow disease progression and keep patients ... Specialty Pharmacy Solutions Elizabeth Mauer told participants at the ... Conference today. "Balancing the tremendous financial burden ...
Cached Medicine Technology:U.S. Marshals Seize Auralgan Otic Solution 2Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference 2
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... September 30, 2014 Integrated Medicine ... is opening another new medical specialty practice through a ... Cardiology will be located within the company’s Shrewsbury ... and Dr. Isaac Tawfik of American Heart Center, P.C., ... new practice will offer Integrated Medicine Alliance patients top ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... EverStryke , the permanent match currently ... along with a free book and class all about survival ... prompting an investigative review. , “Joe Marshall of SurvivalLife.com ... and preparation niche, and this product is an excellent way ... survival products that Joe offers on his website to help ...
(Date:9/30/2014)... The American Diabetes Association ... curb their sweet tooth, but the most recent research, ... suggests that zero-calorie sweeteners may actually be linked to ... The Weizmann Institute of Science in Israel recently ... mice, the mice developed glucose intolerance. They then analyzed ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2
... Medical Data ... the healthcare industry has announced the expansion in to Primary Collections Operations, and the opening ... ... industry leader, Medical Data Systems, Inc. (MDS), has announced the opening of its ...
... Reportlinker.com just added a new market research ... World Multiple Myeloma Therapeutics Market ... , , This ... Therapeutics in Millions of US$. The market for ...
... SCAN Health Plan announced today that it has hired ... services, effective immediately. Taylor-Laws brings more than 25 years ... vice president Taylor-Laws will be responsible for the development ... on behalf of SCAN,s members throughout Maricopa County. "Access ...
... 7 Twenty-one regional hospitals that utilize ... (INHS) earned the distinction of being among the most ... the 2009 Most Wired Survey and Benchmarking Study released ... Networks magazine. Hospitals and Health Networks ...
... for American Medical Innovation headlined a forum on medical ... Health. Former Democratic Majority Leader Richard Gephardt, president ... in Indiana government, academia and business for a panel ... and what is needed to maintain a robust environment ...
... The Anthropedia Foundation, a non-profit organization based in ... Yourself , an innovative DVD series designed for people ... lives. The series is a step-by-step guide to improving ... on straightforward concepts and simple exercises that foster calmness, ...
Cached Medicine News:Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 3Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 2Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 3Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 4Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 5Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 6Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 7Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 8Health News:New Report Just Published: World Multiple Myeloma Therapeutics Market Report 9Health News:SCAN Health Plan Selects Kathy Taylor-Laws as Vice President of Network Management Services 2Health News:21 Regional Hospitals Recognized as Nation's Most Wired 2Health News:21 Regional Hospitals Recognized as Nation's Most Wired 3Health News:Council for American Medical Innovation and Hoosiers Work for Health Host Indiana Forum on Medical Innovation 2Health News:Knowing Yourself Can Improve Your Health and Happiness 2Health News:Knowing Yourself Can Improve Your Health and Happiness 3
... oxygen flowmeters., ,Options: , ... S to model number. Example: ... add suffix C to model ... Double Flowmeters with Power Take-Off, ...
... flowmeters., ,Options: , For ... to model number. Example: FMC107S. ... suffix C to model number. ... Flowmeters with Power Take-Off, add ...
... Slim Line Flowmeters with brass and ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... Flowmeters with brass and aluminum body., ... add suffix S to model number. ... add suffix C to model number. ... with Power Take-Off, add PT to ...
Medicine Products: